share_log

人福医药(600079.SH):恩扎卢胺软胶囊获得药品注册证书

Renfu Pharmaceutical (600079.SH): Enzalutamide softgels obtained drug registration certificate

Gelonghui Finance ·  Mar 5 05:24

Gelonghui, March 5 | Renfu Pharmaceutical (600079.SH) announced that Yichang Renfu recently received the “Drug Registration Certificate” for enzalumide softgels approved and issued by the State Drug Administration. Enzalutamide is an androgen receptor inhibitor suitable for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (NM-CPRC) with a high risk of metastatic metastasis; it is also suitable for the treatment of adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms after failure of androgen deprivation therapy (ADT) and have not received chemotherapy.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment